Clinical Trials Logo

Neuralgia clinical trials

View clinical trials related to Neuralgia.

Filter by:

NCT ID: NCT06410859 Enrolling by invitation - Clinical trials for Trigeminal Neuralgia

Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia

Start date: April 25, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.

NCT ID: NCT06410222 Enrolling by invitation - Clinical trials for Post Herpetic Neuralgia

Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.

Start date: March 1, 2024
Phase:
Study type: Observational

Shingles is a neuropathic disease caused by varicella-herpes virus(VZV) invading nerves and accompanying pain.Currently, the treatment of postherpetic neuralgia (PHN) includes medication and minimally invasive interventional therapy.In patients with herpes zoster neuralgia treated with spinal cord stimulation (SCS), some patients have satisfactory pain relief after surgery, but some patients have pain symptoms again some time after surgery. The reason for this difference in treatment effect is not clear.

NCT ID: NCT06407167 Recruiting - Neuropathic Pain Clinical Trials

Neuropathic Pain in Patients With Degenerative Lumbar Stenosis

Start date: May 13, 2024
Phase:
Study type: Observational

Pre- and postoperative pain in patients with degenerative stenosis requires great attention, as it can mislead the doctor about treatment tactics. Neuropathic pain in the legs before and after the surgical procedure, as well as the residual or recurrent pain syndrome existing against this background, overshadow the patient's recovery and cast doubt on the fullness of the performed decompression. Neural compression in the spinal canal and back pain may be the cause of the patient's antalgic posture and sagittal imbalance as seen on X-Ray, to need for corrective interventions surgical procedure. Thus, it is necessary to clarify the role and the influence of the pain and its type on the perioperative period in patients with degenerative lumbar spinal stenosis.

NCT ID: NCT06402448 Recruiting - Joint Pain Clinical Trials

Prevalence of Muscle and Nerve and Joint Pain

Start date: February 1, 2024
Phase:
Study type: Observational

The purpose of the study is to provide adequate information about the percentage of the main tissue that causing pain in most common spinal disorders either it is muscular, nerve or joint in each spinal parts, that will provide the physical therapist with large data that can be helpful in differential diagnosis.

NCT ID: NCT06398847 Not yet recruiting - Neuropathic Pain Clinical Trials

Virtual Reality (VR) Self-Hypnosis Software

Start date: May 2024
Phase: N/A
Study type: Interventional

This single-site study of self-hypnosis software using an off-the-shelf virtual reality (VR) device (OculusGoâ„¢) to determine the software's safety, usability, and preliminary efficacy in pain relief for HIV-associated chronic pain patients. This is funded under the i Prism Funding through Mount Sinai Innovations.

NCT ID: NCT06390150 Not yet recruiting - Pain, Postoperative Clinical Trials

Spinal Cord Stimulation Pioneering Analgesia for Resilient Recovery in Post Intra-Thoracic Surgery Pain

SPARK
Start date: June 2024
Phase: N/A
Study type: Interventional

This study aims to determine the effectiveness of spinal cord stimulation in patients with post intra-thoracic surgery pain syndrome in a placebo-controlled, crossover, randomized clinical trial.

NCT ID: NCT06367998 Not yet recruiting - Neuropathic Pain Clinical Trials

Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair

Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

This study aims to investigate the effects of Pregabalin intake on shoulder pain management in patients with central sensitization undergoing arthroscopic rotator cuff repair. Although Pregabalin is known to be effective in controlling pain after shoulder arthroscopy, research on its efficacy in pain management for patients with central sensitization is scarce. Utilizing a list that identifies central sensitization, this study will explore whether Pregabalin can reduce postoperative pain in these patients and potentially improve joint mobility, emotional, and physical functioning. A prospective randomized study is planned, with inclusion criteria set for patients aged between 19 and 70 who have undergone arthroscopic rotator cuff repair. The study will compare clinical outcomes up to one year postoperatively between two groups of 38 patients each. The case group will receive standard postoperative medications (NSAIDs) plus Pregabalin oral intake from the day before surgery to six weeks postoperatively, while the control group will receive only the standard postoperative medications without Pregabalin.

NCT ID: NCT06366139 Completed - Clinical trials for Trigeminal Neuralgia

Trigeminal Ganglion RFT vs Maxillary/Mandibular PRF in the Treatment of Trigeminal Neuralgia

Start date: January 11, 2023
Phase: N/A
Study type: Interventional

Trigeminal ganglion (TG) radiofrequency thermocoagulation (RFT) and ultrasound (US)-guided maxillary or mandibular (max/mand) pulsed radiofrequency (PRF) are two interventional procedures for the treatment of trigeminal neuralgia (TN). The aim of this study was to compare the efficacy and safety of these two procedures. For this evaluation, the numeric rating scale (NRS) was used to assess pain relief and the Medication Quantification Scale III (MQS III) was used to assess the effectiveness of the interventions on medication consumption. The rates of adverse events related to the interventions were also compared.

NCT ID: NCT06361108 Not yet recruiting - Clinical trials for Diabetic Peripheral Neuropathic Pain

Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of YJ001 for Spray Use in Patients With Diabetic Peripheral Neuropathic Pain

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

NCT ID: NCT06357260 Recruiting - Clinical trials for Trigeminal Neuralgia

Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Trigeminal neuralgia is a very painful condition associated with paroxysmal severe episodes of pain. Carbamazepine has been the first line of drug for Trigeminal Neuralgia. However, there are several adverse effects linked with Carbamazepine like drowsiness, accommodation disorders, hepatitis, derangement in hepatic enzymes, renal dysfunction. Pregabalin which is an established drug in neuropathic pain has better pharmacokinetic nature which allows for easy management and rapid dose escalation to therapeutic doses. There have been only few trials evaluating efficacy of Pregabalin in classical trigeminal neuralgia. Thus, the present study is designed to evaluate the efficacy of Pregabalin as an add-on therapy to carbamazepine in patients suffering from Trigeminal Neuralgia. In present trial 50 patients fulfilling the exclusion and inclusion criteria will be recruited in two arms that is test group and the control group. The test group will be prescribed carbamazepine along with fixed dose of Pregabalin 75mg twice daily while the control group will be prescribed carbamazepine only. The dose of carbamazepine will be titrated in both groups as per patients need. The outcome regarding pain relief, quality of life and adverse effects and mean dose of carbamazepine required in both groups will be evaluated.